Plus, on a slow news day, underwhelming Senate action on patent reform
And it doesn't look like the hits are going to end anytime soon
Plus a huge poll shows just how many Americans are touched by insurance-company barriers to pharmaceutical access
Plus: children's hospitals have zero problem gouging insurers on 340B-discounted cancer meds for kids
Plus Lilly bags a big Alzheimer's approval ... and is proactive about pricing
And, yeah, more Orange Book stuff from the FTC that ignores industry's concerns
Plus a reminder to treat lowball estimates of drug development costs with some skepticism
And Minnesota's list of drugs with problematic prices is ... actually helpful (?!)
And speaking of numbers, a front-page NYT obesity story could have used more of them
And a new paper takes a stab at guessing the 'ceiling prices' for the first round of IRA price controls
And guess what? Drug prices are going down! Still!
And a good news (but low context) Express Scripts release on patient OOP spending
